179. Back to Basics - Metastatic NSCLC feat. ...

For over a decade, sorafenib remained unchallenged as first-line therapy for hepatocellular carcinoma, based on the SHARP trial, which showed survival increasing from 7.9 to 10.7 months. This demonstrated modest efficacy in a disease notoriously resistant to systemic treatment. T ...  Show more

Until recently, biliary tract cancers were relegated to orphan cancer status: rare cancers such as cholangiocarcinoma and gallbladder cancers. These aggressive malignancies were lumped together, historic trials were small, and patients were stuck with gemcitabine-cisplatin chemot ...  Show more

We have another guest joining us this week! Dr. Allison Schepers, PharmD, BCOP is a Clinical Pharmacist Specialist at the Rogel Cancer Center at the University of Michigan where she focuses on GI, GU, and Thoracic malignancies! In this episode, Allison discusses the high yield ...

There's been a breakthrough in cancer research! Hear all about it and learn some vocabulary with Neil and Beth. Find a full transcript, worksheet and interactive quiz for this episode at: https://www.bbc.co.uk/learningenglish/english/features/6-minute-english_2025/ep-250227Check ...  Show more

In this episode, we discuss Intraperitoneal chemotherapy (IPC) and Heated Intraperitoneal Chemotherapy (HIPEC), including clinical trials of these agents in ovarian cancer, complications and practical tips for utilizing HIPEC in clinical practice. Join us for bi-weekly episodes o ...  Show more

Join Drs Benjamin Schlechter and Jeff Meyerhardt as they discuss the latest breakthroughs in adjuvant chemo for CRC and share their decision-making in real-world scenarios. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarti ...  Show more